Sirolimus-eluting implant - Vascular Therapies

Drug Profile

Sirolimus-eluting implant - Vascular Therapies

Alternative Names: Coll-R

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vascular Therapies
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial disorders; Arteriovenous fistula
  • New Molecular Entity No

Highest Development Phases

  • Phase III Arteriovenous fistula
  • Clinical Phase Unknown Peripheral arterial disorders

Most Recent Events

  • 16 Nov 2017 Sirolimus-eluting implant - Vascular Therapies receives Orphan Drug status for Peripheral arterial disorders in European Union before November 2017
  • 16 Nov 2017 Efficacy data from a clinical trial in Peripheral arterial disorders released by Vascular Therapeutics (Vascular Therapeutics website, November 2017)
  • 09 Nov 2017 Efficacy data from a phase II trial in Arteriovenous fistula released by Vascular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top